APO RESEARCH · REPORT
Critical Limb Ischemia Treatment
Critical limb ischemia (CLI) is a severe blockage in the arteries of the lower extremities, which markedly reduces blood-flow. It is a serious form of peripheral arterial disease, or PAD. PAD caused by atherosclerosis, the hardening and narrowing of the arteries over time due to the buildup of fatty deposits called plaque.Currently, the standard of care for patients battling CLI is balloon angioplasty, which relies on a small balloon delivered via a catheter to the blockage to compress it against the arterial wall, opening the vessel and restoring blood flow.
Product & engineering
Understand the product.
Critical limb ischemia (CLI) is a severe blockage in the arteries of the lower extremities, which markedly reduces blood-flow. It is a serious form of peripheral arterial disease, or PAD. PAD caused by atherosclerosis, the hardening and narrowing of the arteries over time due to the buildup of fatty deposits called plaque.Currently, the standard of care for patients battling CLI is balloon angioplasty, which relies on a small balloon delivered via a catheter to the blockage to compress it against the arterial wall, opening the vessel and restoring blood flow.
Selected research
Industry Research
Critical Limb Ischemia Treatment Industry Research Report 2026
Market perspective
Critical limb ischemia (CLI) is a severe blockage in the arteries of the lower extremities, which markedly reduces blood-flow. It is a serious form of peripheral arterial disease, or PAD. PAD caused by atherosclerosis, the hardening and narrowing of the arteries over time due to the buildup of fatty deposits called plaque.Currently, the standard of care for patients battling CLI is balloon angioplasty, which relies on a small balloon delivered via a catheter to the blockage to compress it against the arterial wall, opening the vessel and restoring blood flow.
Global critical limb ischemia treatment includes Medtronic, Boston Scientific, Abbott, COOK and Cardiovascular Systems, etc. Global top 3 companies hold a share over 59%. North America is the largest market, with a share about 39%, followed by Europe and Asia-Pacific with the share about 31% and 22%.
Report Scope
Read the full market overview
This report quantifies the global Critical Limb Ischemia Treatment market in terms of revenue (US$ million) and, where applicable, service volume (), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Critical Limb Ischemia Treatment.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Critical Limb Ischemia Treatment Market by Company
Medtronic
Boston Scientific
Abbott
COOK
Cardiovascular Systems
Terumo
B. Braun
Biotronik
MicroPort Medical
Lepu Medical
Micro Medical Solutions
Critical Limb Ischemia Treatment Segment by Type
Embolic Protection Devices
Peripheral Dilatation Systems
Drugs Treatment
Other
Critical Limb Ischemia Treatment Segment by Application
ASCs
Hospitals
Catheterization Laboratory
Critical Limb Ischemia Treatment Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Critical Limb Ischemia Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Critical Limb Ischemia Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Critical Limb Ischemia Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Critical Limb Ischemia Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Embolic Protection Devices
- Peripheral Dilatation Systems
- Drugs Treatment
- Other
Applications
- ASCs
- Hospitals
- Catheterization Laboratory
Companies covered
- Medtronic
- Boston Scientific
- Abbott
- COOK
- Cardiovascular Systems
- Terumo
- B. Braun
- Biotronik
- MicroPort Medical
- Lepu Medical
- Micro Medical Solutions
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Critical Limb Ischemia Treatment by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Embolic Protection Devices
- 2.2.3 Peripheral Dilatation Systems
- 2.2.4 Drugs Treatment
- 2.2.5 Other
- 2.3 Critical Limb Ischemia Treatment by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 ASCs
- 2.3.3 Hospitals
- 2.3.4 Catheterization Laboratory
- 2.4 Assumptions and Limitations
3 Critical Limb Ischemia Treatment Breakdown Data by Type
- 3.1 Global Critical Limb Ischemia Treatment Historic Market Size by Type (2021-2026)
- 3.2 Global Critical Limb Ischemia Treatment Forecasted Market Size by Type (2027-2032)
4 Critical Limb Ischemia Treatment Breakdown Data by Application
- 4.1 Global Critical Limb Ischemia Treatment Historic Market Size by Application (2021-2026)
- 4.2 Global Critical Limb Ischemia Treatment Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Critical Limb Ischemia Treatment Market Perspective (2021-2032)
- 5.2 Global Critical Limb Ischemia Treatment Growth Trends by Region
- 5.2.1 Global Critical Limb Ischemia Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Critical Limb Ischemia Treatment Historic Market Size by Region (2021-2026)
- 5.2.3 Critical Limb Ischemia Treatment Forecasted Market Size by Region (2027-2032)
- 5.3 Critical Limb Ischemia Treatment Market Dynamics
- 5.3.1 Critical Limb Ischemia Treatment Industry Trends
- 5.3.2 Critical Limb Ischemia Treatment Market Drivers
- 5.3.3 Critical Limb Ischemia Treatment Market Challenges
- 5.3.4 Critical Limb Ischemia Treatment Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Critical Limb Ischemia Treatment Players by Revenue
- 6.1.1 Global Top Critical Limb Ischemia Treatment Players by Revenue (2021-2026)
- 6.1.2 Global Critical Limb Ischemia Treatment Revenue Market Share by Players (2021-2026)
- 6.2 Global Critical Limb Ischemia Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Critical Limb Ischemia Treatment Head Office and Area Served
- 6.4 Global Critical Limb Ischemia Treatment Players, Product Type & Application
- 6.5 Global Critical Limb Ischemia Treatment Manufacturers Established Date
- 6.6 Global Critical Limb Ischemia Treatment Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Critical Limb Ischemia Treatment Market Size (2021-2032)
- 7.2 North America Critical Limb Ischemia Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Critical Limb Ischemia Treatment Market Size by Country (2021-2026)
- 7.4 North America Critical Limb Ischemia Treatment Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Critical Limb Ischemia Treatment Market Size (2021-2032)
- 8.2 Europe Critical Limb Ischemia Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Critical Limb Ischemia Treatment Market Size by Country (2021-2026)
- 8.4 Europe Critical Limb Ischemia Treatment Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Critical Limb Ischemia Treatment Market Size (2021-2032)
- 9.2 Asia-Pacific Critical Limb Ischemia Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Critical Limb Ischemia Treatment Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Critical Limb Ischemia Treatment Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Critical Limb Ischemia Treatment Market Size (2021-2032)
- 10.2 South America Critical Limb Ischemia Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Critical Limb Ischemia Treatment Market Size by Country (2021-2026)
- 10.4 South America Critical Limb Ischemia Treatment Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Critical Limb Ischemia Treatment Market Size (2021-2032)
- 11.2 Middle East & Africa Critical Limb Ischemia Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Critical Limb Ischemia Treatment Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Critical Limb Ischemia Treatment Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Medtronic
- 12.1.1 Medtronic Company Information
- 12.1.2 Medtronic Business Overview
- 12.1.3 Medtronic Revenue in Critical Limb Ischemia Treatment Business (2021-2026)
- 12.1.4 Medtronic Critical Limb Ischemia Treatment Product Portfolio
- 12.1.5 Medtronic Recent Developments
- 12.2 Boston Scientific
- 12.2.1 Boston Scientific Company Information
- 12.2.2 Boston Scientific Business Overview
- 12.2.3 Boston Scientific Revenue in Critical Limb Ischemia Treatment Business (2021-2026)
- 12.2.4 Boston Scientific Critical Limb Ischemia Treatment Product Portfolio
- 12.2.5 Boston Scientific Recent Developments
- 12.3 Abbott
- 12.3.1 Abbott Company Information
- 12.3.2 Abbott Business Overview
- 12.3.3 Abbott Revenue in Critical Limb Ischemia Treatment Business (2021-2026)
- 12.3.4 Abbott Critical Limb Ischemia Treatment Product Portfolio
- 12.3.5 Abbott Recent Developments
- 12.4 COOK
- 12.4.1 COOK Company Information
- 12.4.2 COOK Business Overview
- 12.4.3 COOK Revenue in Critical Limb Ischemia Treatment Business (2021-2026)
- 12.4.4 COOK Critical Limb Ischemia Treatment Product Portfolio
- 12.4.5 COOK Recent Developments
- 12.5 Cardiovascular Systems
- 12.5.1 Cardiovascular Systems Company Information
- 12.5.2 Cardiovascular Systems Business Overview
- 12.5.3 Cardiovascular Systems Revenue in Critical Limb Ischemia Treatment Business (2021-2026)
- 12.5.4 Cardiovascular Systems Critical Limb Ischemia Treatment Product Portfolio
- 12.5.5 Cardiovascular Systems Recent Developments
- 12.6 Terumo
- 12.6.1 Terumo Company Information
- 12.6.2 Terumo Business Overview
- 12.6.3 Terumo Revenue in Critical Limb Ischemia Treatment Business (2021-2026)
- 12.6.4 Terumo Critical Limb Ischemia Treatment Product Portfolio
- 12.6.5 Terumo Recent Developments
- 12.7 B. Braun
- 12.7.1 B. Braun Company Information
- 12.7.2 B. Braun Business Overview
- 12.7.3 B. Braun Revenue in Critical Limb Ischemia Treatment Business (2021-2026)
- 12.7.4 B. Braun Critical Limb Ischemia Treatment Product Portfolio
- 12.7.5 B. Braun Recent Developments
- 12.8 Biotronik
- 12.8.1 Biotronik Company Information
- 12.8.2 Biotronik Business Overview
- 12.8.3 Biotronik Revenue in Critical Limb Ischemia Treatment Business (2021-2026)
- 12.8.4 Biotronik Critical Limb Ischemia Treatment Product Portfolio
- 12.8.5 Biotronik Recent Developments
- 12.9 MicroPort Medical
- 12.9.1 MicroPort Medical Company Information
- 12.9.2 MicroPort Medical Business Overview
- 12.9.3 MicroPort Medical Revenue in Critical Limb Ischemia Treatment Business (2021-2026)
- 12.9.4 MicroPort Medical Critical Limb Ischemia Treatment Product Portfolio
- 12.9.5 MicroPort Medical Recent Developments
- 12.10 Lepu Medical
- 12.10.1 Lepu Medical Company Information
- 12.10.2 Lepu Medical Business Overview
- 12.10.3 Lepu Medical Revenue in Critical Limb Ischemia Treatment Business (2021-2026)
- 12.10.4 Lepu Medical Critical Limb Ischemia Treatment Product Portfolio
- 12.10.5 Lepu Medical Recent Developments
- 12.11 Micro Medical Solutions
- 12.11.1 Micro Medical Solutions Company Information
- 12.11.2 Micro Medical Solutions Business Overview
- 12.11.3 Micro Medical Solutions Revenue in Critical Limb Ischemia Treatment Business (2021-2026)
- 12.11.4 Micro Medical Solutions Critical Limb Ischemia Treatment Product Portfolio
- 12.11.5 Micro Medical Solutions Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst